How Sickness Became A Business
July 20, 2026
For decades, the leading causes of chronic disease have been well ascertained. The mechanisms of cancer have been mapped at the molecular level. The toxic chemicals added to products have been identified. The links between processed food and obesity have been measured. The solutions have been documented. Yet the diseases persist, the death tolls continue and the industries most responsible grow larger and more profitable every year.
A great example is the tobacco industry. Commercial cigarettes are not simply dried tobacco leaves rolled in natural paper. They are highly engineered products with over 100 chemical additives, designed by scientists who totally understand what they are creating. Since exact formulas are often proprietary and kept secret, what is known comes largely from documents released through litigation and partial regulatory disclosures.
- Fake sugars (sucrose, glucose, high-fructose corn syrup) are added to tobacco to make a sweeter, milder smoke that can be inhaled deeply into the lungs.
- Ammonia compounds are added so that nicotine is faster-absorbing and more addictive.
- Menthol is used to numb throat irritation and reduce coughing, suppressing the body's natural protective response.
- Potassium nitrate is added so that cigarettes burn between puffs, generating nitrosamines that are among the most potent carcinogens.
In the 1980s, when smoking began to wane, tobacco companies diversified. They acquired General Foods, Kraft and Nabisco brands, and the accumulated knowledge from years of engineering addictive products didn't go to waste. Food scientists working for these companies refined the precise formula of sugar, salt and fat to maximize the urge to keep eating while suppressing natural satiety signals. Artificial emulsifiers, preservatives and flavor compounds were added to foods in combinations that prioritized taste and shelf life, over long-term biological effects.
The results are measurable. Obesity rates in the United States have tripled since the 1970s. Type 2 diabetes, once almost unheard of in children, is now a pediatric health crisis. Colorectal cancer rates are rising sharply in young adults in patterns that track closely with ultra-processed food consumption. The United States spends more on healthcare per capita than any nation on earth, while life expectancy and good health have declined.
The old strategy was: Create the problem - profit from the solution. But now the management of chronic illness is what generates the big bucks. The global cancer treatment market exceeds $200 billion annually. The diabetes drug market exceeds $60 billion. Cardiovascular, autoimmune and depression meds each represent a multi-billion dollar revenue stream generated by conditions, that in many cases, have documented preventions that receive a mere fraction of the research funding and clinical attention that pharmaceutical management does.
The reason is structural, financial and rather sinister. Drug development is expensive and funded by companies that recover their investment through patent-protected sales. A patented drug generating revenue for twenty years represents a return on investment. An inexpensive, off-patent drug for the treatment of cancer represents an expenditure with no return. A nutritional plan that prevents diabetes represents no pharmaceutical revenue at all. The research pipeline reflects these incentives with disturbing accurancy - it is systematically skewed toward patentable, high-cost, long-term treatments and away from prevention, cures and simple medicines. This isn't just speculation. Researchers, health economists and physicians state it plainly. The incentives are visible, the outcomes are measurable and the pattern has been consistent for decades.
When promising signs emerged in oncology research regarding antiparasitic drugs, (mebendazole, fenbendazole, ivermectin, hydroxychloroquine), that showed anticancer activity in lab tests and case reports, large-scale clinical trials didn't follow. Not because the science was dismissed, but because these drugs are off-patent, cheap and generically available. No company stood to profit from proving they worked. The trials that can answer that question remain underfunded, while patented, costly treatments receive extensive industry backing.
Cancer is actually understood at the molecular level with enough precision to design drugs that target specific mutations in specific genes. The knowledge exists. What has not existed for a very long time, is the financial incentive to apply that knowledge toward getting people well, rather than managing their sickness for profit. A patient cured is a customer lost. A patient chronically managed is a customer retained. This is not healthcare. It's a business strategy for fiscal gains.
Pharmaceutical companies have long suppressed unfavorable trial results in cases that cost billions of dollars in legal settlements - costs that were still lower than the revenue the concealment protected. They have spent hundreds of millions annually lobbying the legislators who set drug pricing policy and research funding priorities. They have moved executives through revolving doors into regulatory agencies and back, creating relationships that compromise genuine accountability.
The revelations mentioned here are documented facts drawn from court records, public records, released internal files, lobbying disclosures and published research. None of this is hidden. It is simply rarely compiled into a single coherent picture for all to see and really understand.
The question that remains isn't whether these industries prioritize profit over lives. The evidence on that point is sufficient. The question is, what is being done about it?